N/A N=28 Feeling and Body Investigators for Pediatric Abdominal Pain
Functional Abdominal Pain
Primary: Number of Participants Who Complete Treatment — 22 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=292 Functional Dyspepsia Treatment Trial
Dyspepsia and Other Specified Disorders of Function of Stomach
Primary: Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment — 53; 38; 40 percentage of participants — p=0.05
N/A N=158 Clinical Improvement and in Quality of Life-Functional Dyspepsia-
Psychogenic Dyspepsia
Primary: Change From Baseline in DYSPEPSIA RELATED HEALTH SCALE (DRHS) — 73.72; 65.31; 71.85; 64.89 units on a scale
N/A N=1,881 Impact of Diet on Functional Gastrointestinal Symptoms
Gastrointestinal Disorder, Functional
Primary: Most Common Triggers for Food-related GI Symptoms (Top 5) — 881; 494; 469; 460 Participants
Phase 3 N=81 Anxiety and Recurrent Abdominal Pain in Children
Abdominal Pain · Anxiety
Primary: Clinical Global Impression Scale - Improvement (CGI-I) Will be Used to Assess Overall Global Illness Improvement. CGI-I Scores of 1 (Very Much Improved) or 2 (Much…
N/A N=31 Efficacy of Open Label Placebo in Children With FGIDs
Functional Abdominal Pain · Functional Dyspepsia · Irritable Bowel Syndrome
Primary: The Primary Outcome Measure Was Mean Daily Pain — 39.9; 45.14 pain scale by VAS in mm — p=<0.03
N/A N=33 Systematic Pediatric Assessment of Rome Criteria (SPARC)
Functional Gastrointestinal Disorders
Primary: Resolution of Symptoms From Initial Rome IV Diagnosis at 3 Months Using an Age-appropriate Rome IV Questionnaire. Number of Participants Who no Longer Meet Rome IV…
N/A N=115 Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?
Chronic Abdominal Pain · Small Intestinal Bacterial Overgrowth
Primary: The Number of Participants at Baseline With SIBO — 14; 44; 24 Participants
N/A N=115 Efficacy of Ear Neurostimulation for Adolescents With Functional Abdominal Pain
Functional Disorder of Intestine · Nausea Persistent
Primary: Pain Frequency-Severity-Duration Scale (PFSD) Score — 5.0; 7.0 units on a scale — p=0.003
Phase 2 N=175 (Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis
Abdominal Pain
Primary: Change From Baseline in Intensity of Abdominal Pain Associated With Cramping Following Treatment Based on the Numeric Pain Rating Scale (NPRS) in Episode 1 — -2.7; -3.1…
N/A N=20 Visceral Manipulation in Patients With Chronic Low Back Pain
Chronic Low Back Pain
Primary: Low Back Pain After 6 Weeks of Intervention — 6.50; 6.00; 1.50; 3.50 units on a scale
N/A N=23 Functional Dyspepsia Hypnosis
Functional Dyspepsia
Primary: Percent of Participants That Complete the Hypnotherapy Program — 22 Participants
Phase 2 N=20 Effect of Secretin in Functional Dyspepsia and Healthy Subjects
Dyspepsia · Healthy
Primary: Maximum Satiation — 892.5; 951.75; 655.5; 892.5 mL — p=0.12
N/A N=8 Evaluation of S-adenosyl Methionine (SAM-e) for Recurrent Abdominal Pain in Children
Abdominal Pain
Primary: Wong-Baker FACES Pain Rating Scale — 3; 3; 4; 4 units on a scale — p=0.004
N/A N=90 Internet Based Cognitive Behavioral Therapy in Pediatric Chronic Pancreatitis
Chronic Pancreatitis · Acute Recurrent Pancreatitis
Primary: Change in Adolescent Abdominal Pain Severity — 2.11; 1.74; 1.99; 1.61 scores on a scale
Phase 4 N=262 Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia
Dyspepsia · Compliance · Depression
Primary: Compliance of Flupentixol-Melitracen — 44; 28; 31 participants
N/A N=48 Evaluation of the Gastrointestinal Manifestation of Fabry's Disease
Fabry's Disease
Primary: Gastric Emptying Transit Time Measured Via SmartPill Study — 2.9; 2.8 Hours
Phase 4 N=74 A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing
Irritable Bowel Syndrome
Primary: Change in Mean Daily Abdominal Pain — 5.2; 5.3; 3.9; 3.8 score on a scale — p=0.78
N/A N=99 Fear, Gastrointestinal Distress, and Interoception: Physiological and Psychological Mechanisms in Eating Disorders
Feeding and Eating Disorders
Primary: Subjective Rating of Fear — -36.9444; -23.9219; -47.3611; 85.6250 units on scale*minutes — p=.879
N/A N=26 Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL
N/A N=10 Buspirone for Functional Dysphagia
Functional Dysphagia · Ineffective Esophageal Motility
Primary: Change in Distal Contractile Index (DCI) on High Resolution Esophageal Manometry — 241.9; 340.4 mm Hg
Phase 3 N=123 A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
Functional Constipation (FC) · Chronic Idiopathic Constipation (CIC)
Primary: Change From Baseline in 12-week Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) Observed by the Primary Caregiver During the Double-blind Study Intervention…
N/A N=48 Effects of Low FODMAP Diet on Colonic Epithelial Physiology in Diarrhea-predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome
Primary: Lactulose Mannitol Excretion — 512.5; 394.5; 456.8; 411 micrograms per ml
N/A N=110 Probiotic VSL#3 for the Treatment of Gastrointestinal Symptoms Associated to Fibromyalgia
Fibromyalgia · Gastrointestinal Disease
Primary: Change, From Baseline to Endpoint (12 Weeks) in the Composite Score of Abdominal Pain, Abdominal Bloating and Metheorism Each One Measured in a 0-10 Visual Analog Scale…
Phase 3 N=18 Duloxetine in Patients With Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction)
Sphincter of Oddi Dysfunction
Primary: The Primary Outcome Measure Was a Patient Global Assessment of Change (PGIC) Scale. — 3.3 units on a scale
N/A N=436 Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome
Irritable Bowel Syndrome
Primary: Clinical Global Impressions - Improvement Scale (CGI-I; Patient Version) — 68.1; 64.6; 46.7; 64.0 percentage of treatment responders
Phase 3 N=465 Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders
Functional Bowel Disorder
Primary: Change From Baseline of Sum of NRS-11 Abdominal Pain and Bloating/Flatulence Intensity Scores After 4 Weeks of Treatment. — -7.23; -6.48; -5.86 score on a scale — p=0.0042
N/A N=26 Evaluating the Efficacy of the Mediterranean Diet to the Low- Fermentable, Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAP) Diet in Treating Irritable Bowel Syndrome(IBS)
Irritable Bowel Syndrome
Primary: Proportion of Participants Who Are Responders Based on the Abdominal Pain Intensity Score for at Least 2 of 4 Weeks — 9; 8 Participants — p=1.00
Phase 4 N=19 Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Primary: Gastric Emptying — 0.27; 0.384; 0.04; 0.051 percent meal retention — p=0.003
Phase 2 N=36 Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation
Functional Constipation
Primary: Colonic Transit at 24 Hours — 2.68; 3.12; 1.93 units on a scale — p=0.059